Review: Practical considerations in ovarian cancer chemotherapy

Therapeutic Advances in Medical Oncology

Volumn 2, Issue 3, 2010, Pages 175-187

  Cristea, Mihaela ^a   Han, Ernest ^a   Salmon, Lennie ^a   Morgan, Robert J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

chemotherapy; intraperitoneal; ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; NAB PACLITAXEL; OLAPARIB; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEMETREXED; PLACEBO; TOPOTECAN; UNCLASSIFIED DRUG;

ANEMIA; ANOREXIA; AREA UNDER THE CURVE; CANCER STAGING; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FATIGUE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYELOSUPRESSION; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSORY NEUROPATHY; VOMITING;

EID: 77955632263     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834010361333     Document Type: Review

References (69)

1. Aabo, K., Adnitt, P., Adams, M., Alberts, D.S., Barley, V., Bell, D.R. et al. (1991) Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 303: 884-893.
2. Alberts, D.S., Green, S., Hannigan, E.V., O'Toole, R., Stock-Novack, D., Jolles, C.J. et al. (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10: 706-717.
3. Alberts, D.S., Liu, P.Y., Hannigan, E.V., O'Toole, R., Williams, S.D., Young, J.A. et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl J Med 335: 1950-1955.
4. American Cancer Society. (2009) Cancer Facts and Figures 2009. Atlanta: American Cancer Society.
5. Armstrong, D.K., Bundy, B., Wenzel, L., Huang, H.Q., Baergen, R., Burger, R.A. et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43.
6. Audeh, M., Penson, R., Friedlander, M., Powell, B., Bell-Mcguinn, K., Scott, C. et al. (2009) Phase II trial of the oral parp inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 27(Suppl 18S): 5500.
7. Bell, J., Brady, M.F., Young, R.C., Lage, J., Walker, J.L., Spirtos, N.M. et al. (2006) Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 102: 432-439.
8. Bertelsen, K., Grenman, S. and Rustin, G.J. ( 1999) How long should first-line chemotherapy continue? Ann Oncol 10(Suppl 1): 17-20.
9. Blum, J.L., Savin, M.A., Edelman, G., Pippen, J.E., Robert, N., O'Shaughnessy, J.A. et al. (2004) Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. Proc Am Soc Clin Oncol 22: 543 (Abstr.).
10. Bolis, G., Danese, S., Tateo, S., Rabaiotti, E., D'Agostino, G., Merisio, C. et al. (2006) Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int J Gynecol Cancer 16(Suppl 1): 74-78.
11. Bookman, M.A., Brady, M.F., McGuire, W.P., Harper, P.G., Alberts, D.S., Roth, L.M. et al. (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27: 1419-1425, Erratum in: J Clin Oncol 27 (13): 2305.
12. Buckstein, R., Meyer, R.M., Seymour, L., Biagi, J., Mackay, H., Laurie, S. et al. (2007) Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group Ind Program Trials Ind.182-185. Curr Oncol 14: 154-161.
13. Cannistra, S.A., Matulonis, U.A., Penson, R.T., Hambleton, J., Dupont, J., Mackey, H. et al. (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25: 5180-5186.
14. Casper, E.S., Kelsen, D.P., Alcock, N.W. and Lewis, J.L. ( 1983) IP cisplatin in patients with malignant ascites; pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep 67: 235-238.
15. Decker, D.G., Fleming, T.R., Malkasian, G.D., Webb, M.J., Jeffries, J.A. and Edmonson, J.H. ( 1982) Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol 60: 481-487.
16. Du Bois, A., Lück, H.-J., Meier, W., Adams, H.-P., Möbus, V., Pfisterer, J. et al. (2003) A randomized clinical trial of cisplatin / paclitaxel versus carboplatin / paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329.
17. Fong, P., Boss, D., Carden, C., Roelvink, M., de Greve, J., Gourley, C. et al. (2008) AZD 2281 (Ku-0059436), a parp (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study. J Clin Oncol 26: 5510.
18. Fong, P., Boss, D., Yap, T., Tutt, A., Wu, P., Mergui-Roelvink, M. et al. (2009) Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl J Med 361: 123.
19. Francis, P., Rowinsky, E., Schneider, J., Hakes, T., Hoskins, W. and Markman, M. ( 1995) Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Onocol 13: 2961-2967.
20. Friedlander, M., Hancock, K., Benigno, B., Rischin, D., Messing, M., Stringer, C. et al. (2007) Pazopanib (Gw786034) is active in women with advanced epithelial ovarian, fallopian tube, and peritoneal cancers: initial results of a phase II study. J Clin Onocol 25(Suppl 18S): 5561.
21. Fujiwara, K., Nagao, S., Kigawa, J., Noma, J., Akamatu, N., Miyagi, Y. et al. (2009) Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study group study. Int J Gynecol Cancer 19: 834-837.
22. Garcia, A.A., Hirte, H., Fleming, G., Yang, D., Tsao-Wei, D.D., Roman, L. et al. (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 26: 76-82.
23. Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., O'Shaughnessy, J.A. et al. (2005) Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor-oil-based paclitaxel in women with metastatic breast cancer: results of a phase III trial. J Clin Oncol 23: 7794-7803.
24. Hennenfent, K.L. and Govindan, R. ( 2006) Novel formulations of taxanes: old wine in a new bottle ? Ann Oncol 17: 735-749.
25. Herzog, T.J. ( 2006) The current treatment of recurrent ovarian cancer. Curr Oncol Rep 8: 448-454.
26. Howell, S.B., Pfeifle, C.E., Wung, W.E., Olshen, R.A., Lucas, W.E., Yon, J.L. et al. (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97: 845-851.
27. Howell, S.B., Pfeifle, C.E., Wung, W.E. and Olshen, R.A. ( 1983) Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43: 1426-1431.
28. Ibrahim, N.K., Samuels, B. and Page, R. ( 2002) Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer: efficacy and evidence of dose-dependent activity in two multicenter phase II studies. Proc Am Soc Clin Oncol 20: 209 (Abstr.).
29. Kaye, S.B., Piccart, M., Aapro, M., Francis, P. and Kavanagh, J. ( 1997) Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer-an updated overview. Eur J Cancer 33: 2167-2170.
30. Lopez, J.A., Krikorian, J.G., Reich, S.D., Smyth, R.D., Lee, F.H. and Issell, B.F. ( 1985) Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol 20: 1-9.
31. Markman, M. ( 2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4: 277-283.
32. Markman, M., Bundy, B.N., Alberts, D.S., Fowler, J.M., Clark-Pearson, D.L., Sickel, J. et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001-1007.
33. Markman, M., Liu, P.Y., Moon, J., Monk, B.J., Copeland, L., Wilczynski, S. et al. (2009) Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 114: 195-198.
34. Markman, M., Liu, P.Y., Wilczynski, S., Monk, B., Copeland, L.J.C., Alberts, D. et al. (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21: 2460-2465.
35. Markman, M., Rowinsky, E., Hakes, T., Reichman, B., Jones, W., Lewis, J.L. et al. (1992) Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 10: 1485-1491.
36. Matei, D., Sill, M., Degeest, K. and Bristow, R. ( 2008) Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J Clin Oncol 26: 5537.
37. Matulonis, U.A., Berlin, S., Ivy, P., Tyburski, K., Krasner, C., Zarwan, C. et al. (2009) Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27: 5601-5606.
38. Matulonis, U.A., Horowitz, N.S., Campos, S.M., Lee, H., Lee, J., Penson, R.T. et al. (2008) Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol 26: 5761-5766.
39. McGuire, W.P., Hoskins, W.J., Brady, M.F., Kucera, P.R., Partridge, E.E., Davidson, M. et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6.
40. Miller, D.S., Blessing, J.A., Krasner, C.N. and Mannel, R.J. ( 2008) A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the gynecologic oncology group. Proc Am Soc Clin Oncol 26: 5524 (Abstr.).
41. Nicoletto, M.O., Tumolo, S., Falci, C., Donach, M., Visona, E., Rosabian, A. et al. (2004) A randomized study of epithelial ovarian cancer: is chemotherapy useful after complete remission? Int J Med Sci 1: 116-125.
42. Omura, G.A., Bundy, B.N., Berek, J.S., Curry, S., Delgado, G. and Mortel, R. ( 1989) Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 7: 457-465.
43. Ozols, R.F., Bookman, M.A., Young, R.C., du Bois, A., Pfisterer, J. and Reuss, A. ( 2006) Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 103: 1-6.
44. Ozols, R.F., Bundy, B.N., Greer, B.E., Fowler, J.M., Clarke-Pearson, D., Baergen, R. et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200.
45. Parmar, M.K., Ledermann, J.A., Colombo, N., du Bois, A., Delaloye, J.F., Trope, C. et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/ AGO-OVAR-2.2 trial. Lancet 361: 2099-2106.
46. Pecorelli, S., Favalli, G., Gadducci, A., Katsaros, D., Benedetti Panici, P., Conte, P. et al. (2009) Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the after-6 protocol 1. J Clin Oncol 27 (28): 4642-4648.
47. Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Eisenhauer, E. et al. (2006) Gemcitabine / carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO OVAR, NCIC CTG, and EORTC GCG. J Clin Oncol 24: 4699-4707.
48. Piccart, M.J., Bertelsen, K., James, K., Cassidy, J., Mangioni, C., Pecorelli, S. et al. (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699-708.
49. Pretorius, R.G., Hacker, N.F., Berek, J.S., Ford, L.C., Hoeschele, J.D., Butler, T.A. et al. (1983) Pharmacokinetcs of IP cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 67: 1085-1092.
50. Richardson, D.L., Backes, F.J., Seamon, L.G., Zanagnolo, V., O'Malley, D.M., Cohn, D.E. et al. (2008) Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol 111: 461-466.
51. Richardson, D.L., Seamon, L.G., Carlson, M.J., O'Malley, D.M., Fowler, J.M., Copeland, L.J. et al. (2008) CA 125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. Gynecol Oncol 111: 233-236.
52. Rose, P.G., Blessing, J.A., Ball, H.G., Hoffman, J., Warshal, D., de Geest, K. et al. (2003) A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 88: 130-135.
53. Rose, P.G., Nerenstone, S., Brady, M.F., Clarke-Pearson, D., Olt, G., Small, J.M. et al. (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. New Engl J Med 351: 2489-2497+2567.
54. Rossof, A.H., Talley, R.W., Stephens, R., Thigpen, T., Samson, M.K., Eyre, H.J. et al. (1979) Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study. Cancer Treat Rep 63: 1557-1564.
55. Sabbatini, P., Aghajanian, C., Dizon, D., Anderson, S., Dupont, J., Spriggs, D. et al. (2004) Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 22: 4523-4525.
56. Schneider, J.G. ( 1994) Intraperitoneal chemotherapy. Obstet Gynecol Clin North Am 21: 195-212.
57. Schreiber, V., Dantzer, F., Ame, J. and de Murcia, G. ( 2006) Poly (ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7: 517-528.
58. Teneriello, M.G., Tseng, P.C., Crozier, M., Encarnacion, C., Hancock, K., Asmar, L. et al. (2007) Results of a phase II evaluation of nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. Proc Am Soc Clin Oncol 25: 5525 (Abstr.).
59. Thigpen, T., Shingleton, H., Homesley, H., LaGasse, L. and Blessing, J. ( 1979) Cisdichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep 63: 1549-1555.
60. Tiersten, A.D., Liu, P.Y., Smith, H.O., Wilczynski, S.P., Robinson, W.R., Markman, M. et al. (2009) Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol 112: 444-449.
61. Tournigand, C., Louvet, C., Molitor, J.L., Fritel, X., Dehni, N., Sezeur, A. et al. (2003) Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission. Gynecol Oncol 91: 341-345.
62. Trimble, E.L. and Alvarez, R.D. ( 2006) Intraperitoneal chemotherapy and the NCI clinical announcement. Gynecol Oncol 103(2 Suppl 1): S18-S19.
63. van der Burg, M.E.L., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Pecorelli, S. et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. New Engl J Med 332: 629-634.
64. Varughese, M.A., Jonathan, A. and Ledermann, J.A. (2009) Trial design strategies for vascular-targeted therapy of patients with ovarian cancer. Clin Ovarian Cancer 2: 24-30.
65. Vasey, P.A., Jayson, G.C., Gordon, A., Gabra, H., Coleman, R., Kaye, S.B. et al. (2004) On behalf of the Scottish Gynaecological Cancer Trials group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682-1691.
66. Vergote, I., Calvert, H., Kania, M., Kaiser, C., Zimmermann, A.H., Sehouli, J.A. et al. (2009) Randomized, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 45: 1330-1332.
67. Vergote, I., Trope, C.G., Amant, F., Kristensen, G.B., Sardi, J.E., Reed, N.S. et al. (2008) EORTC-GCG/ NCIC-CTG randomized trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer. Plenary presentation at the 12th Biennial Meeting International Gynecologic Cancer Society, Bangkok, Thailand, 25-28 October (Abstr.).
68. Walker, J.L. ( 2009) Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol Oncol 112: 439-440.
69. Walker, J.L., Armstrong, D.K., Huang, H.Q., Fowler, J., Webster, K., Burger, R.A. et al. (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 100: 27-32.